At a glance
ClinicalIndex Comparison RecordN/ACompleted· 62 enrolled
Drug / intervention
CellFX Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Non-Randomized, Multicenter Pivotal Study of Nano-Pulse Stimulation™ (NPS™) Treatment of Cutaneous Non-Genital Warts
In Brief
A clinical study evaluating CellFX Device for Warts and 2 related conditions. Completed, enrolled 62 participants across 5 sites.
Detailed Summary
This prospective, non-randomized, multicenter pivotal study is designed to evaluate the safety and effectiveness of the CellFX System in patients with cutaneous non-genital warts on all areas of the body, excluding the face.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWarts, Warts Hand, Verruca
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartJul 2019
Primary CompletionJun 2020
First PostedSep 2020
Study CompletionDec 2020
TodayJul 2026
First PostedSep 18, 2020
Enrollment StartJul 17, 2019
Primary CompletionJun 9, 2020
Study CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.8 years ago
Interventions
CellFX Devicedevice
The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.